argenx Surges to $520M Trading Volume, Climbs to 343rd in Market Volume Rankings

On Sept. 19, 2025, , . , reflecting heightened investor engagement amid a broader market recovery in healthcare equities.

The spike in liquidity followed a strategic update from argenx’s clinical pipeline, . , a key differentiator in competitive autoimmune therapies.

Short-term volatility remains tied to regulatory timelines, particularly the U.S. Food and Drug Administration’s review of efgartigimod’s Biologics License Application. , .

To build an accurate back-test I need to lock down a few practical details about the trading rule and the data universe. 1. Universe • Should we consider all U.S. common stocks (≈4,000 tickers), or a narrower group (e.g., , S&P 1500, etc.)? • Do we include ETFs, ADRs, or only primary listed common shares? 2. , ? , ? 3. , ? 4. , or would you like to include an estimate (e.g., ? Let me know your preferences on the above and I’ll generate the data-retrieval plan and run the back-test.